The ISN Advancing Clinical Trials Toolkit is designed to assist in carrying out meaningful and robust clinical trials, or to become involved as a trial site, with the primary intention of improving patient care. Available online for the first time at the ISN World Congress of Nephrology (WCN), Congress delegates are invited to experience the...
A two-day meeting was held in Vancouver, Canada, from January 31 to February 1, 2020, which brought together the ISN executive leadership, members of ISN Research groups, patients, clinicians, clinical trialists, academics, industry, and regulators to establish momentum for international collaborative work in clinical trials and research in kidney disease across the world. The meeting...
A two-day meeting is to be held in Vancouver, Canada, from January 31 to February 1, 2020, bringing together members of ISN Research groups, patients, clinicians, clinical trialists, academics, industry, and regulators to establish momentum for international collaborative work in clinical trials and research in kidney disease across the world. The meeting will introduce current...
Every month the ISN-ACT Team lists interesting new randomized controlled trials from around the world. Highlights: Brace for it: an external support device may help fistulas to mature Getting things straight when it comes to peritoneal dialysis catheters See the latest trials here
A multidisciplinary group of researchers and clinicians met in October 2018 to identify evidence and address controversies in potassium management providing research priorities and guidance for evaluation and management of dyskalemias in the context of kidney diseases.
The ISN Global Kidney Health Atlas (GKHA) 2019 manuscript “Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey” was published in The BMJ on October 31. The second edition of the GKHA reports on global kidney health across 160 countries representing 98% of the world’s population. The report focuses on care for end-stage kidney...
Kidney International (KI) is pleased to announce the publication of a study on hypertension, led by the ISN iNET-CKD (International Network of chronic kidney disease cohort studies). This study highlights considerable international variation in hypertension control and treatment in chronic kidney disease (CKD). The new study from the ISN iNET-CKD highlights substantial variation in the prevalence...
The editors of Kidney International (KI) would like to share a selection of articles from the August edition of the publication. Articles focus on a broad range of topics from renal pathology practice globally, the genomic landscape of CAKUT, identifying geospatial “hotspots” of glomerular diseases, the disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of...
In July 2019, the second series of clinical trials curated by the ISN Advancing Clinical Trials (ISN-ACT) team will get us thinking about nephrology research and encourage more discussion about transplant, glomerular diseases and pediatric nephrology: from the role of EPO post-transplant, tacrolimus dosing in Asian transplant recipients to the optimal duration of steroids...
PRESS RELEASE July 9, 2019 Kidney Patients are Neglected in Clinical Trials The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients. Over 850 million people suffer from kidney diseases worldwide, a number which signifies epidemic proportions, yet these patients are still ignored by investigators and...
This month, the first series of clinical trials curated by the ISN-Advancing Clinical Trials (ISN-ACT) team will get us thinking about nephrology research and encourage more discussion about chronic kidney disease, dialysis and hypertension: from PD catheter exit site care, the effectiveness of Roxadustat, to the initial treatment of hypertension in Sub-Saharan Africans and...
This month, we have lots of new educational material for you to delve into. From new in-depth reviews in Kidney International (KI) to June's KI editor’s picks. Big science and big data in nephrology Over the next few months, Kidney International (KI) will feature in-depth reviews on big science, artificial intelligence, and machine learning. This review, the first in this series, provides...
Kidney International (KI) has published a paper, as a Supplement to its journal, focusing on increasing patient access to integrated end-stage kidney disease care (ESKD) and how this fits in with Universal Health Coverage . Authored by David Harris et al., the paper is entitled 'Increasing access to integrated ESKD care as part of Universal...
Thanks to his ISN Hydration for Kidney Health (H4KH) Fellowship, Amarasiri De Silva spent several days at the Danone Nutricia Research Center in France. It was a valuable and unique opportunity to meet other researchers and share his work on chronic kidney disease of unknown origin in Sri Lanka. As partners, Danone Nutricia Research and...
An executive summary of the 2018 KDIGO hepatitis C in CKD guideline: Welcoming advances in evaluation and management is now available in Kidney International. Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a...
With the amount of people needing dialysis set to double by 2030, the need for a cost-effective system has never been greater. Once market ready, this innovation could change access to treatment transforming dialysis practices in rural and remote settings and developing countries. Three years ago, research was published in The Lancet showing an overwhelming...
September's issue of Kidney international (KI) will feature an important article from Ziyad Al-Aly and colleagues, which uses Global Burden of Disease (GBD) data to show, in just one generation since 1990, an almost doubling of the incidence, prevalence and mortality of chronic kidney disease (CKD), and a more than 60% increase in disability-adjusted...
The 2017 impact factors have now been published. Find out more about how our publications have been rated! Kidney International’s (KI) 2017 Impact Factor has increased to 8.429 (a small increase over the 2016 IF of 8.395). Kidney International Supplements 2017 Impact Factor is 3.357 (a decrease from the 2016 IF of 5.593). KI ranks now...
Kidney diseases have so far been underestimated in many respects: most people are not aware of their impaired kidney function. In general, kidney diseases are “silent diseases”, most often there are no apparent early symptoms. Many people with kidney diseases are not aware that they have been living with higher risks of cardiovascular diseases, infections,...
Following March's second Global Kidney Health Summit in the United Arab Emirates, the outputs from this meeting are currently being written for publication. In the meantime, here is what came out the first Global Kidney Health Summit held in Canada in 2016. During the first ISN Global Kidney Health Summit, a selected group of 85 international key...
